Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/nrc.2017.125.

Title:
Targeting minimal residual disease: a path to cure? | Nature Reviews Cancer
Description:
Improved therapies have allowed many patients with cancer to achieve complete remission, but they retain minimal residual disease (MRD), which causes relapse. This Opinion article argues that iterative detection, profiling and targeting of MRD could improve outcomes, including cure rates. Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌆 Monumental Traffic: 20M - 50M visitors per month


Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$536,300 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $357,503 to $983,134.

Keywords {🔍}

pubmed, article, scholar, google, cas, cancer, central, leukemia, oncol, residual, acute, nature, disease, nat, cell, clin, blood, minimal, patients, cells, myeloid, singlecell, lymphoblastic, clinical, chemotherapy, med, therapy, access, phase, study, rev, content, treatment, research, breast, tumor, circulating, mrd, lung, trial, engl, sci, usa, chronic, results, heterogeneity, detection, versus, flow, response,

Topics {✒️}

nature portfolio journals permissions reprints nature portfolio privacy policy index tonsillar carcinomas interrogating open issues author information authors advertising single-cell rna-seq supports integrative cancer research national library scientific adviser receives research funding social media open-label dana-farber cancer institute nature+ nature 435 nature 539 nature 518 nature single-cell rna-seq guide therapy decision-making research hospital intraductal papillary-mucinous tumors live-cell mass profiling single-cell transcriptomics applied empowering single-cell 'omics' low-cost rna sequencing small-cell lung cancer gov/ct2/show/nct02478125 muscle-invasive bladder cancer single-cell mass accumulation stop 2g-tki study xenografts enables discovery single-cell growth rates circulating-free tumor dna early breast cancer moving treatment-free remission real-time deformability cytometry permissions egfr-mutant nsclc patients springerlink instant access fixable bh3 profiling gastrointestinal stromal tumors predicting patient responses flow cytometric monitoring chronic myeloid leukaemia metastatic breast cancer phase iii randomized

Questions {❓}

  • Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?
  • Has MRD monitoring superseded other prognostic factors in adult ALL?
  • MRD in AML: does it already guide therapy decision-making?
  • Targeting minimal residual disease: a path to cure?
  • Targeting minimal residual disease: a path to cure?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Targeting minimal residual disease: a path to cure?
         description:Improved therapies have allowed many patients with cancer to achieve complete remission, but they retain minimal residual disease (MRD), which causes relapse. This Opinion article argues that iterative detection, profiling and targeting of MRD could improve outcomes, including cure rates. Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.
         datePublished:2018-01-29T00:00:00Z
         dateModified:2018-01-29T00:00:00Z
         pageStart:255
         pageEnd:263
         sameAs:https://doi.org/10.1038/nrc.2017.125
         keywords:
            Assay systems
            Cancer therapy
            Leukaemia
            Nanobiotechnology
            Tumour heterogeneity
            Biomedicine
            general
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc.2017.125/MediaObjects/41568_2018_Article_BFnrc2017125_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc.2017.125/MediaObjects/41568_2018_Article_BFnrc2017125_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc.2017.125/MediaObjects/41568_2018_Article_BFnrc2017125_Fig3_HTML.jpg
         isPartOf:
            name:Nature Reviews Cancer
            issn:
               1474-1768
               1474-175X
            volumeNumber:18
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Marlise R. Luskin
               affiliation:
                     name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
                     address:
                        name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Mark A. Murakami
               affiliation:
                     name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
                     address:
                        name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Scott R. Manalis
               affiliation:
                     name:Cambridge, Massachusetts 02139, USA.
                     address:
                        name:Scott R. Manalis is at the Koch Institute for Integrative Cancer Research and the Departments of Biological Engineering and Mechanical Engineering at the Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.,
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:David M. Weinstock
               affiliation:
                     name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.
                     address:
                        name:David M. Weinstock is at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.,
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Targeting minimal residual disease: a path to cure?
      description:Improved therapies have allowed many patients with cancer to achieve complete remission, but they retain minimal residual disease (MRD), which causes relapse. This Opinion article argues that iterative detection, profiling and targeting of MRD could improve outcomes, including cure rates. Therapeutics that block kinases, transcriptional modifiers, immune checkpoints and other biological vulnerabilities are transforming cancer treatment. As a result, many patients achieve dramatic responses, including complete radiographical or pathological remission, yet retain minimal residual disease (MRD), which results in relapse. New functional approaches can characterize clonal heterogeneity and predict therapeutic sensitivity of MRD at a single-cell level. Preliminary evidence suggests that iterative detection, profiling and targeting of MRD would meaningfully improve outcomes and may even lead to cure.
      datePublished:2018-01-29T00:00:00Z
      dateModified:2018-01-29T00:00:00Z
      pageStart:255
      pageEnd:263
      sameAs:https://doi.org/10.1038/nrc.2017.125
      keywords:
         Assay systems
         Cancer therapy
         Leukaemia
         Nanobiotechnology
         Tumour heterogeneity
         Biomedicine
         general
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc.2017.125/MediaObjects/41568_2018_Article_BFnrc2017125_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc.2017.125/MediaObjects/41568_2018_Article_BFnrc2017125_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc.2017.125/MediaObjects/41568_2018_Article_BFnrc2017125_Fig3_HTML.jpg
      isPartOf:
         name:Nature Reviews Cancer
         issn:
            1474-1768
            1474-175X
         volumeNumber:18
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Marlise R. Luskin
            affiliation:
                  name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
                  address:
                     name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Mark A. Murakami
            affiliation:
                  name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
                  address:
                     name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Scott R. Manalis
            affiliation:
                  name:Cambridge, Massachusetts 02139, USA.
                  address:
                     name:Scott R. Manalis is at the Koch Institute for Integrative Cancer Research and the Departments of Biological Engineering and Mechanical Engineering at the Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.,
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:David M. Weinstock
            affiliation:
                  name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.
                  address:
                     name:David M. Weinstock is at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.,
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Cancer
      issn:
         1474-1768
         1474-175X
      volumeNumber:18
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
      address:
         name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
      address:
         name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
         type:PostalAddress
      name:Cambridge, Massachusetts 02139, USA.
      address:
         name:Scott R. Manalis is at the Koch Institute for Integrative Cancer Research and the Departments of Biological Engineering and Mechanical Engineering at the Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.,
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.
      address:
         name:David M. Weinstock is at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.,
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Marlise R. Luskin
      affiliation:
            name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
            address:
               name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
               type:PostalAddress
            type:Organization
      name:Mark A. Murakami
      affiliation:
            name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.
            address:
               name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
               type:PostalAddress
            type:Organization
      name:Scott R. Manalis
      affiliation:
            name:Cambridge, Massachusetts 02139, USA.
            address:
               name:Scott R. Manalis is at the Koch Institute for Integrative Cancer Research and the Departments of Biological Engineering and Mechanical Engineering at the Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.,
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:David M. Weinstock
      affiliation:
            name:Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.
            address:
               name:David M. Weinstock is at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.,
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
      name:Marlise R. Luskin and Mark A. Murakami are at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.,
      name:Scott R. Manalis is at the Koch Institute for Integrative Cancer Research and the Departments of Biological Engineering and Mechanical Engineering at the Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.,
      name:David M. Weinstock is at the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA, and at the Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA.,
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(454)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

7.49s.